Últimas noticias sobre Vivopower Intl (NASDAQ:VVPR) Bolsa

Vivopower Intl

Vivopower International PLC is a solar power company. The company provides energy infrastructure generation, and distribution solutions and is also engaged in the development, construction, and sale of photovoltaic(PV) solar projects. Its operating segments include Solar Development, Critical Power Services, Sustainable Energy Solutions Electric Vehicles, and Corporate Office. The majority of the firm's revenue is generated from the Critical Power Services segment which consists of the design, supply, installation, and maintenance of power and control systems. It provides its solutions to government, commercial, and industrial customers. Nearly all of the revenue derives from Australia.

Vivopower International

VivoPower International PLC - Ordinary Shares

Vivopower International PLC

JP Morgan analyst Phil Gresh maintains Canadian Natural Res (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CNQ#TSX">CNQ</a>) with a Neutral and raises the price target from C$51 to C$53.

News

Price Target

Analyst Ratings

TSX:CNQ

JP Morgan Maintains Neutral on Canadian Natural Res, Raises Price Target to C$53

Oppenheimer analyst Rayna Kumar maintains Fiserv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>) with a Outperform and raises the price target from $214 to $239.

Oppenheimer Maintains Outperform on Fiserv, Raises Price Target to $239

In the current market session, Verisk Analytics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSK#NASDAQ">VRSK</a>) share price is at $275.67, after a 0.04% spike. Moreover, over the past month, the stock fell by 4.14%, but in the past year, spiked by 16.71%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2024/1734627613_0.png" alt="Past Year Chart" />

<h3>Comparing Verisk Analytics P/E Against Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of 39.2 in the Professional Services industry, Verisk Analytics Inc. has a higher P/E ratio of 42.53. Shareholders might be inclined to think that Verisk Analytics Inc. might perform better than its industry group. It's also possible that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1734627613_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

VRSK

P/E Ratio Insights for Verisk Analytics

A Georgia state appeals court has removed Fulton County District Attorney Fani Willis from the election interference case against President-elect Donald Trump, citing an "appearance of impropriety" as the <a href="https://www.benzinga.com/topic/fani-willis">basis for the decision. </a>
The court emphasized that disqualification was necessary to restore public confidence, but the indictment itself remains intact, leaving the case's future in question, the Associated Press <a href="https://apnews.com/article/trump-fani-willis-georgia-election-indictment-removed-0aa6db3b7abed22eb08ed9323f687972">reports</a>.
What Happened: In a 2-1 ruling, the Georgia Court of Appeals found that Willis&#8217;s involvement created concerns over impartiality. The decision mandates the Prosecuting Attorneys' Council of Georgia to assign a new prosecutor to the case, potentially delaying proceedings further if Willis appeals to the state Supreme Court.
The legal challenge stems from allegations that her prior romantic relationship with special prosecutor Nathan Wade influenced pretrial decisions, the AP reports.
The indictment, issued in August 2023, accuses Trump and 18 others of attempting to overturn the 2020 presidential election results in Georgia. Four defendants have since pleaded guilty, while Trump and the others maintain their innocence. 
Superior Court Judge Scott McAfee had previously allowed Willis to remain on the case, a decision now overruled by the appeals court.
Manhattan District Attorney Alvin Bragg&#8216;s response to similar legal arguments further complicates Trump&#8217;s broader legal battles. In New York, Bragg argued that overwhelming evidence of guilt in the hush money case involving adult film actress Stormy Daniels supersedes <a href="https://www.benzinga.com/24/12/42521426/trumps-hush-money-conviction-upheld-amid-presidential-immunity-controversy-alvin-bragg-says-overwhelming-evidence-of-guilt">claims of presidential immunity.</a>
Also Read: <a href="https://www.benzinga.com/24/12/42568430/senate-minority-leader-mcconnell-urges-supreme-court-to-reject-tiktoks-delay-request-pushing-for-january-ban-amid-first-amendment-debate">Mitch McConnell Urges Supreme Court To Reject TikTok&#8217;s Delay Request</a>
Why It Matters: Trump has celebrated the Georgia court's decision, calling for the case to end entirely. While this marks a victory for the president-elect, experts note the ruling may only delay, rather than halt, proceedings, according to the AP. The case also impacts the remaining 14 co-defendants, who continue to face serious charges.
The broader implications extend beyond Georgia, with Trump facing ongoing legal challenges in New York and Washington, D.C. His legal team continues to argue for presidential immunity in these cases. They&#8217;re also seeking to shield him from prosecution as he prepares to return to the White House.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/legal/24/12/42405278/trump-plays-presidential-immunity-card-in-truth-social-lawsuit-battle">Trump Plays Presidential Immunity Card In Truth Social Lawsuit Battle</a></li>
</ul>
Photo: Shutterstock

Politics

Legal

Trump Prosecutor Fani Willis Removed From Election Case, Indictment Stands

Cannabis regulators and industry advocates have, for a long time, contended that <a href="https://www.benzinga.com/cannabis">licensed marijuana products</a> are safer and cleaner than those circulating on the illicit market. Logical, right? Not necessarily. An analysis published Thursday by the Los Angeles Times challenges that claim and reveals comparable pesticide contamination rates in legal and illicit cannabis.
Testing 16 products from unlicensed sellers and tobacco shops, the Times <a href="https://www.latimes.com/california/story/2024-12-19/legal-and-illegal-cannabis-products-pose-hidden-health-risks">found</a> that half had no detectable pesticides, mirroring the pesticide-free rate in California's legal market. This, despite California&#8217;s tests for 66 pesticides in licensed products, which fail to detect other harmful compounds identified in the Times investigation.
This similarity apparently "doesn't shock" Josh Swider, CEO and cofounder of Infinite Chemical Analysis Labs, which tests cannabis in California and Michigan. "Normally, the illicit market is just buying from the legal market brokers. It's not like there really are two different markets," he said, according to the Times.
California's Department of Cannabis Control naturally defends the regulated market, stating that its oversight ensures "far greater consumer safety than the unregulated alternative." 
<h2 class="wp-block-heading">Logical? Not Quite</h2>
Some unregulated products were pesticide-free because they contained synthetic THC variants, such as Delta-8, derived from chemically processed hemp. These compounds, while inexpensive to produce, carry unknown health risks due to these chemical byproducts. "It's not a pesticide problem, but it has other health implications," Swider said.
Notably, synthetic THC is not confined to the illicit market. The Times report uncovered lab-created cannabinoids in vape pens sold by various legal brands. While synthetic THC is banned in California's legal market, the state doesn't screen for it, hence not so logical. 
Michigan regulators, on the other hand, have validated tests to identify these compounds.
<h2 class="wp-block-heading">Health Hazards</h2>
The analysis also uncovered troubling health hazards. The Times looked at a vape from an unlicensed East LA shop that contained vitamin E acetate, which was linked to severe lung injuries, thousands of hospitalizations and 68 deaths during the <a href="https://www.benzinga.com/markets/cannabis/19/12/14909104/ask-new-frontier-data-experts-vaping-crisis-update">2019 vape crisis</a>. The state of California does not screen for Vitamin E acetate, which is used to dilute vape cartridges.
Ironically, the most pesticide-laden products came from legal sellers. One brand, Backpack Boyz vape bought at a licensed shop contained 32 pesticides. State regulators quickly shut down the manufacturer, though Backpack Boyz claimed the contaminated products were counterfeits, according to the LA Times.
Pesticide types varied between markets, with illicit products often containing banned chemicals from California's screening list. In contrast, legal products were often found to contain unscreened pesticides like pymetrozine, a carcinogenic insecticide that did not show up in any unregulated cannabis products.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/10/41555499/all-once-again-warned-unregulated-cannabis-vapes-contain-dangerous-pesticides-study-says">All Once Again Warned: Unregulated Cannabis Vapes Contain Dangerous Pesticides, Study Says</a></li>
</ul>
Photo AI generated via Dall-E.

Cannabis

Government

Pesticides In Pot: Overlooked Dangers Of California's Legal Weed

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Structure Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPCR#NASDAQ">GPCR</a>) with a Buy and maintains $80 price target.

Reiteration

GPCR

HC Wainwright & Co. Reiterates Buy on Structure Therapeutics, Maintains $80 Price Target

FWONA

Liberty Media Confirms European Commission Phase II Investigation Into MotoGP Acquisition, Extends Longstop Date To June 30, 2025

Soho House &amp; Co Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHCO#NYSE">SHCO</a>) shares are trading higher after the company received a $9.00 per share acquisition offer from a new third-party consortium, an 83% premium to the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42576367/soho-house-co-inc-announcement-on-offer-from-a-third-party-consortium-to-acquire-the-company" rel="noreferrer noopener">December 18, 2024, closing price</a>.
Supported by the company&#8217;s Executive Chairman, Ron Burkle and The Yucaipa Companies, the offer follows a strategic review by Yucaipa and its advisors, aiming to better reflect the company&#8217;s inherent value.
In response to the offer, which is contingent on key shareholders rolling over their equity interests, the Board of Directors has established an independent Special Committee to evaluate the proposal.
Also, the company reported third-quarter EPS&nbsp;of $0.00 beating the street view of a loss of $0.01 and sales&nbsp;of $333.4 million missing the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42576891/soho-house-co-inc-announces-third-quarter-2024-results" rel="noreferrer noopener">consensus of $334.87 million</a>.
Membership revenues rose 16.7% year-over-year to <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">$107.4 million in the quarter</a>.
In the third quarter, total members increased 4.8% year-over-year to 267,494, and Soho House members grew 13% year-over-year to 208,078.
The membership waitlist remains at a record level of approximately 111,000.
At the end of the third-quarter of 2024, Soho House had cash and cash equivalents, including restricted cash, of $147 million.
During the quarter, the company repurchased approximately 2.3 million shares for $13 million.
Outlook: Soho House updated its FY24 revenue guidance to around $1.2 billion (vs. the consensus estimate of $1.23 billion), narrowing from its <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">previous range of $1.2 billion to $1.25 billion</a>.
Price Action: SHCO shares are up 58.4% at $7.77 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42593013" target="_blank" rel="noreferrer noopener">Luigi Mangione Faces Extradition, Possible Federal Charges May Carry Death Penalty</a></li>
</ul>
Photo via Shutterstock.

Earnings

Equities

Guidance

Small Cap

Movers

SHCO

Soho House Jumps On Receiving Acquisition Offer With 83% Premium

Shares of Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) are trading flat on Thursday, but remain in a downtrend.
If the stock eventually reaches levels around $95.00, there is a good chance it reverses and heads higher. As you can see on the chart, this is what happened in late November. This is why our technical analysis team has made it our <a href="https://www.benzinga.com/topic/stock-of-the-day">Stock of the Day</a>.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="557" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19115400/14-1024x557.png" alt="Merck" class="wp-image-700197" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19115400/14-1024x557.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19115400/14-300x163.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19115400/14-768x418.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19115400/14.png 1491w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
There has been a lot of news coming from Merck.
The advanced cancer genomic testing provider Personalis, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>) said it received a $50 million equity investment from Merck.&nbsp; When the deal closes, Merck will own 16.5% of Personalis.
Merck also announced that <a href="https://www.benzinga.com/24/12/42554599/whats-going-on-with-merck-shares-wednesday">it is entering the lucrative obesity market</a>. It is licensing rights from Chinese biotech Hansoh Pharmaceutical Group Company Limited&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/HNSPF#OTC">HNSPF</a>)to an investigational oral GLP – 1 receptor.
The chart of Merck offers some simple but valuable technical analysis lessons. Price levels that had been resistance can convert into support. Also, stocks that drop to support have a tendency to rally.
Read Also: <a href="https://www.benzinga.com/general/biotech/24/12/42561832/teva-pharmaceutical-releases-impressive-phase-2-candidate-data-for-gastro-related-diseases">Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases</a>
$119.40 was resistance in May 2023. Some of the investors who sold then were happy when the price fell soon after. They thought they made a good decision.
But in January 2024 the resistance broke and the stock moved higher. When this happened, some of these sellers came to think they made a mistake and decided to buy their shares back if they can do so at the same price they sold them for.
So, when the stock dropped back to around $119.40 in March 2024 they placed buy orders. The large concentration of these orders formed support at the same price that had been resistance.
Similar action occurred at the $111.00 level. It was resistance in August 2023. Then it became support a year later in August 2024.
In July 2022, the $95.00 level was resistance. It converted into support last month, and it may be support again if Merck reaches it.
As you can also see on the chart, sometimes stocks rally after they reach support. This happens when some of the buyers who created the support think they will get outbid. If someone else is willing to pay a higher price, that's who the sellers will go to.
As a result, they increase the prices they are willing to pay. Others see this and do the same. It can cause a snowball effect that pushes the stock higher and it may be about to happen with Merck.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42595485/bitcoin-rebounds-above-102000-post-fed-meeting-us-gdp-hits-31-jobless-claims-drop-treasury-yields-peak-teslas-eu-registrations-fall-41-q4-ev-target-in-doubt-top-headlines-today-while-us-slept">Bitcoin Rebounds Above $102,000 Post-Fed Meeting; Us GDP Hits 3.1%, Jobless Claims Drop, Treasury Yields Peak &#8211; Top Headlines Today While US Slept</a></li>
</ul>
Image: Courtesy of Merck.

Technicals

Trading Ideas

HNSPF

PSNL

Stock Of The Day: Where Does The Merck Downtrend End?

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) with a Buy and maintains $12 price target.

IMNN

HC Wainwright & Co. Reiterates Buy on Imunon, Maintains $12 Price Target

Oppenheimer analyst Rayna Kumar maintains Euronet Worldwide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EEFT#NASDAQ">EEFT</a>) with a Outperform and lowers the price target from $135 to $128.

EEFT

Oppenheimer Maintains Outperform on Euronet Worldwide, Lowers Price Target to $128

Oppenheimer analyst Rayna Kumar upgrades Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>) from Perform to Outperform and announces $115 price target.

Upgrades

Oppenheimer Upgrades Block to Outperform, Announces $115 Price Target

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) with a Buy and maintains $80 price target.

CLDX

HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $80 Price Target

Whales with a lot of money to spend have taken a noticeably bullish stance on Schlumberger.
Looking at options history for Schlumberger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) we detected 17 trades.
If we consider the specifics of each trade, it is accurate to state that 47% of the investors opened trades with bullish expectations and 47% with bearish.
From the overall spotted trades, 12 are puts, for a total amount of $798,050 and 5, calls, for a total amount of $1,117,614.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $25.0 and $47.5 for Schlumberger, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Schlumberger's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Schlumberger's significant trades, within a strike price range of $25.0 to $47.5, over the past month.
<h3>Schlumberger Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734626823_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SLB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$0.99</td>
<td>$0.91</td>
<td>$0.97</td>
<td>$47.50</td>
<td>$970.0K</td>
<td align="right">519</td>
<td>10.0K</td>
</tr>
<tr>
<td>SLB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$10.55</td>
<td>$10.5</td>
<td>$10.55</td>
<td>$47.50</td>
<td>$211.0K</td>
<td align="right">907</td>
<td>122</td>
</tr>
<tr>
<td>SLB</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$8.45</td>
<td>$8.25</td>
<td>$8.47</td>
<td>$45.00</td>
<td>$64.3K</td>
<td align="right">663</td>
<td>92</td>
</tr>
<tr>
<td>SLB</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$10.8</td>
<td>$10.7</td>
<td>$10.7</td>
<td>$47.50</td>
<td>$58.8K</td>
<td align="right">907</td>
<td>479</td>
</tr>
<tr>
<td>SLB</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$10.8</td>
<td>$10.7</td>
<td>$10.7</td>
<td>$47.50</td>
<td>$58.8K</td>
<td align="right">907</td>
<td>424</td>
</tr>
</tbody>
</table>

<h3>About Schlumberger</h3>
SLB is the world's premier oilfield-services company as measured by market share. While the industry is mostly fragmented, SLB holds the first or second competitive position in many of the differentiated oligopolies it operates in. Also known as Schlumberger, the company was founded in 1926 by two brothers bearing the same last name. Today it's most known as a global industry leader in innovation, while it focuses its strategy on its three growth engines: its core, digital, and new energy businesses. Over three fourths of its revenue base is tied to international markets, while the company boasts well over $1 billion in digital-related revenue.
In light of the recent options history for Schlumberger, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Schlumberger</h3>
<ul>
<li>With a volume of 5,601,300, the price of SLB is up 0.78% at $37.62. </li>
<li>RSI indicators hint that the underlying stock may be oversold.</li>
<li>Next earnings are expected to be released in 29 days.</li>
</ul>
<h3>Professional Analyst Ratings for Schlumberger</h3>
In the last month, 3 experts released ratings on this stock with an average target price of $50.666666666666664.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for Schlumberger, targeting a price of $53. 
&#x2A; An analyst from Citigroup persists with their Buy rating on Schlumberger, maintaining a target price of $53. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Equal-Weight rating on Schlumberger, which currently sits at a price target of $46. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Schlumberger with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Looking At Schlumberger's Recent Unusual Options Activity

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Armata Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ARMP#AMEX">ARMP</a>) with a Buy and maintains $7 price target.

ARMP

HC Wainwright & Co. Reiterates Buy on Armata Pharmaceuticals, Maintains $7 Price Target

Investors with significant funds have taken a bearish position in First Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>), a development that retail traders should be aware of.
This was brought to our attention today through our monitoring of publicly accessible options data at Benzinga. The exact nature of these investors remains a mystery, but such a major move in FSLR usually indicates foreknowledge of upcoming events.
Today, Benzinga's options scanner identified 9 options transactions for First Solar. This is an unusual occurrence. The sentiment among these large-scale traders is mixed, with 33% being bullish and 66% bearish. Of all the options we discovered, 8 are puts, valued at $399,107, and there was a single call, worth $140,000.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $180.0 to $300.0 for First Solar over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for First Solar's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of First Solar's whale trades within a strike price range from $180.0 to $300.0 in the last 30 days. 
<h3>First Solar Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734626818_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>FSLR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$28.75</td>
<td>$28.0</td>
<td>$28.0</td>
<td>$185.00</td>
<td>$140.0K</td>
<td>25</td>
<td align="right">50</td>
</tr>
<tr>
<td>FSLR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/10/25</td>
<td>$13.9</td>
<td>$13.35</td>
<td>$13.9</td>
<td>$190.00</td>
<td>$90.3K</td>
<td>291</td>
<td align="right">68</td>
</tr>
<tr>
<td>FSLR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$30.35</td>
<td>$29.6</td>
<td>$30.35</td>
<td>$210.00</td>
<td>$81.9K</td>
<td>837</td>
<td align="right">128</td>
</tr>
<tr>
<td>FSLR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$127.75</td>
<td>$125.1</td>
<td>$126.85</td>
<td>$300.00</td>
<td>$63.4K</td>
<td>8</td>
<td align="right">5</td>
</tr>
<tr>
<td>FSLR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$9.45</td>
<td>$8.75</td>
<td>$9.45</td>
<td>$180.00</td>
<td>$47.2K</td>
<td>4.6K</td>
<td align="right">85</td>
</tr>
</tbody>
</table>

<h3>About First Solar</h3>
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and India.
After a thorough review of the options trading surrounding First Solar, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of First Solar</h3>
<ul>
<li>Trading volume stands at 737,927, with FSLR's price down by -1.57%, positioned at $181.38.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 68 days.</li>
</ul>
<h3>What The Experts Say On First Solar</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $242.33333333333334.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Piper Sandler keeps a Overweight rating on First Solar with a target price of $250. 
&#x2A; Maintaining their stance, an analyst from Baird continues to hold a Outperform rating for First Solar, targeting a price of $267. 
&#x2A; Maintaining their stance, an analyst from Piper Sandler continues to hold a Overweight rating for First Solar, targeting a price of $210. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest First Solar options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

FSLR

First Solar's Options: A Look at What the Big Money is Thinking

Investors with a lot of money to spend have taken a bullish stance on Deere (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with DE, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 10 uncommon options trades for Deere.
This isn't normal.
The overall sentiment of these big-money traders is split between 50% bullish and 40%, bearish.
Out of all of the special options we uncovered, 6 are puts, for a total amount of $524,201, and 4 are calls, for a total amount of $397,045.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $380.0 to $470.0 for Deere during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Deere's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Deere's substantial trades, within a strike price spectrum from $380.0 to $470.0 over the preceding 30 days.
<h3>Deere Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734626813_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$14.5</td>
<td>$13.95</td>
<td>$14.5</td>
<td>$390.00</td>
<td>$290.0K</td>
<td>288</td>
<td align="right">200</td>
</tr>
<tr>
<td>DE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$18.6</td>
<td>$17.9</td>
<td>$17.9</td>
<td>$470.00</td>
<td>$177.2K</td>
<td>266</td>
<td align="right">100</td>
</tr>
<tr>
<td>DE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$3.75</td>
<td>$3.6</td>
<td>$3.75</td>
<td>$450.00</td>
<td>$93.7K</td>
<td>1.9K</td>
<td align="right">268</td>
</tr>
<tr>
<td>DE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$18.5</td>
<td>$18.35</td>
<td>$18.35</td>
<td>$470.00</td>
<td>$91.7K</td>
<td>266</td>
<td align="right">100</td>
</tr>
<tr>
<td>DE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$8.3</td>
<td>$7.8</td>
<td>$7.8</td>
<td>$420.00</td>
<td>$65.8K</td>
<td>752</td>
<td align="right">88</td>
</tr>
</tbody>
</table>

<h3>About Deere</h3>
Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry in their green and yellow livery. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 2,000 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.
In light of the recent options history for Deere, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Deere's Current Market Status</h3>
<ul>
<li>Trading volume stands at 472,087, with DE's price up by 0.25%, positioned at $427.05.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 56 days.</li>
</ul>
<h3>What The Experts Say On Deere</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $474.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Truist Securities continues to hold a Buy rating for Deere, targeting a price of $538. 
&#x2A; An analyst from Morgan Stanley has decided to maintain their Overweight rating on Deere, which currently sits at a price target of $450. 
&#x2A; An analyst from JP Morgan persists with their Neutral rating on Deere, maintaining a target price of $450. 
&#x2A; An analyst from Citigroup has decided to maintain their Neutral rating on Deere, which currently sits at a price target of $470. 
&#x2A; An analyst from UBS persists with their Neutral rating on Deere, maintaining a target price of $462. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Deere, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Market Whales and Their Recent Bets on Deere Options

Eaton Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETN#NYSE">ETN</a>) has outperformed the market over the past 5 years by 15.99% on an annualized basis producing an average annual return of 28.94%. Currently, Eaton Corp has a market capitalization of $135.13 billion. 
Buying $1000 In ETN: If an investor had bought $1000 of ETN stock 5 years ago, it would be worth $3,540.00 today based on a price of $339.44 for ETN at the time of writing.
<h3>Eaton Corp's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734626709_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Eaton Corp 5 Years Ago Would Be Worth Today

NVNI

Nvni Group Shares Halted On Circuit Breaker To The Upside, Stock Now Up 496.9%

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) with a Buy and maintains $10 price target.

SGMO

HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target

VivoPower International (VVPR) has released an update. VivoPower International's subsidiary, Caret Digital, is set to transform up to 55MW of its s...

VivoPower's Caret Digital Ventures into Crypto Mining

VivoPower International (VVPR) has released an update. VivoPower International has received a notice from Nasdaq indicating that its stock price ha...

VivoPower Faces Nasdaq Compliance Challenge

Tembo E-LV has secured full on road homologation vehicle type approval for Tembo Tusker 100% electric utility vehicles across the Australia market....

VivoPower's Tembo secures full on road homologation VTA for Tembo Tusker

VivoPower International (VVPR) has released an update. VivoPower International's subsidiary, Tembo, has achieved a significant milestone by securin...

VivoPower's Tembo Tusker Gains Approval in Australia

VivoPower gets Nasdaq noncompliance notice

VivoPower gets Nasdaq non-compliance notice

VivoPower (VVPR) announced that its wholly owned subsidiary, Caret, will commence Dogecoin mining operations with revenue and profitable cashflow g...

VivoPower subsidiary will activate Dogecoin mining operations

VivoPower International PLC (VVPR) Q4 2024 Earnings Call Transcript

VivoPower regains Nasdaq compliance

VivoPower International ( ($VVPR) ) just unveiled an announcement. VivoPower International has regained compliance with Nasdaq's minimum bid price ...

VivoPower Reaches Nasdaq Compliance with $1 Minimum Bid Price

VVPR

Press Releases

VivoPower's Caret Digital to develop up to 55MW of its solar farm portfolio for digital asset mining, including Dogecoin and Litecoin, with potential annual revenues of up to US$150m

VIVOPOWER'S TEMBO SECURES FULL ON ROAD HOMOLOGATION FOR ITS TEMBO TUSKER 100% ELECTRIC VEHICLES IN US$10 bn AUSTRALASIAN PICK UP TRUCK MARKET

VivoPower International PLC Receives Notice from Nasdaq Regarding Compliance with Form 20-F Filing Requirements

VivoPower International PLC To File 20-F Annual Report and Fulfil NASDAQ Compliance Requirements

Vivopower Announces Date For 20-F Annual Results and Strategic Update Presentation

VivoPower's Caret Digital to activate Dogecoin mining operations, with revenue and profitable cashflow generation by early January 2025

VivoPower's Tembo to launch EUV25 EPower kits for Landcruisers at Automechanika Dubai 2024, with an estimated 60,0000 attendees from 160 countries

VivoPower to host Annual General Meeting on December 30, 2024 in London

VivoPower's Caret Digital secures asset backed financing facility for up to 1,000 Antminer L9s to accelerate DOGE coin mining revenues and free cashflows

Comments

Vivopower Intl

Noticias

Últimas noticias sobre Vivopower Intl (NASDAQ:VVPR) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL